Micafungina Teva

Micafungin, the active ingredient in Micafungina Teva, is an echinocandin presented as an intravenous formulation for hospital use. It is employed to treat serious fungal infections such as invasive candidiasis, Candida esophagitis, peritonitis, and febrile neutropenia in immunocompromised patients. It is indicated for patients with systemic fungal infections who require intravenous therapy and is administered under medical supervision. GNH USA supplies Micafungina Teva as a licensed, GDP‑compliant supplier serving hospitals, transplant and oncology centres, pharmacies and clinics worldwide, with regulated quality and temperature‑controlled logistics.

Micafungin is an echinocandin antifungal used to treat invasive Candida infections and related conditions. - Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Candida esophagitis: eradicates Candida infection of the esophagus. - Candida peritonitis: resolves intra‑abdominal Candida infection. - Febrile neutropenia: used as empirical therapy for suspected fungal infection in neutropenic patients.

Micafungin may cause a range of adverse reactions, most of which are manageable.

Common Side Effects: - Infusion‑related reactions: flushing, chills, or dyspnea during administration. - Elevated liver enzymes: transient increases in ALT or AST. - Gastrointestinal symptoms: nausea, vomiting, or abdominal discomfort.

Serious or Rare Side Effects: - Severe hepatic dysfunction: jaundice or hepatic failure. - Anaphylaxis: acute hypersensitivity with respiratory compromise. - Renal impairment: acute kidney injury or worsening renal function. - Hematologic abnormalities: severe neutropenia or thrombocytopenia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Micafungin therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters. - Renal function: monitor serum creatinine in patients with pre‑existing renal impairment. - Hepatic function: check liver enzymes before and during treatment. - Hypersensitivity: discontinue immediately if severe allergic reaction occurs. - Concomitant antifungals: evaluate potential additive toxicity when used with other antifungal agents. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) may markedly reduce micafungin exposure. - Co‑administration with other echinocandins can increase toxicity without added benefit. - Concurrent use with azoles that share metabolic pathways may lead to unpredictable plasma levels.

Moderate Interactions (Monitor Closely): - Immunosuppressants such as cyclosporine may require dose adjustment. - Warfarin therapy may be affected; monitor INR closely. - Nephrotoxic agents (e.g., aminoglycosides) warrant renal function monitoring. - Concomitant use with drugs that prolong QT interval should be evaluated. - Adjust dosing when combined with agents that alter protein binding.